Assess EGFR mutation status. Diarrhoea including severe diarrhoea may result in dehydration w/ or w/o renal impairment. Patients w/ prolonged or severe skin reactions may require temporary interruption of therapy, dose reduction, additional therapeutic intervention & referral to specialist w/ expertise in managing dermatologic effects. Discontinue or interrupt treatment if severe bullous, blistering or exfoliating conditions develop. Female gender, lower body wt & underlying renal impairment. Permanently discontinue treatment if ILD is diagnosed; if GI perforation developed. Interrupt or discontinue treatment if ulcerative keratitis is confirmed. Patients w/ history of keratitis, ulcerative keratitis or severe dry eye. Cardiac monitoring including left ventricular ejection function (LVEF) assessment at baseline & during treatment in patients w/ cardiac risk factors & those w/ conditions that can affect LVEF. Consider interruption or discontinuation in patients w/ an ejection fraction below the institution's LLN. Concomitant treatment w/ strong P-gp inducers. Not to be taken by patients w/ rare hereditary conditions of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption. Periodic liver function testing is recommended in patients w/ pre-existing liver disease. Not recommended in patients w/ eGFR <15 mL/min/1.73 m
2 or on dialysis; patients w/ severe (Child Pugh C) hepatic impairment. Advise women of childbearing potential to avoid becoming pregnant while receiving treatment. Pregnancy. Avoid breastfeeding during treatment. Not recommended in childn & adolescents.
Sign Out
